drugset
drugset / Trial / NCT01541488

Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers

NCT01541488 ↗

Phase 1 Completed 66 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Safety, tolerability, pharmacokinetics and early pharmacodynamics of single rising oral doses of BI 1021958 tablets in healthy male volunteers (first-in-human trial)

Timeline

Start
2012-02
Primary completion
2012-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1021958 Unknown 1 mg Oral
Subject BI 1021958 Unknown 5 mg Oral
Subject BI 1021958 Unknown 20 mg Oral
Subject BI 1021958 Unknown 60 mg Oral
Subject BI 1021958 Unknown 150 mg Oral
Subject BI 1021958 Unknown 300 mg Oral
Subject BI 1021958 Unknown 500 mg Oral

Indications

No indication recorded.